Gefitinib (IRESSA) in advanced non small cell lung cancer (NSCLC): Response, survival and toxicity data

被引：0
|
作者：
Thomas, C [1 ]
Kassam, Z [1 ]
Shah, N [1 ]
机构：
[1] Mt Vernon Canc Ctr, London, England
来源：
BRITISH JOURNAL OF CANCER | 2004年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [2] The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC)
    Skrickova, J
    Tomiskova, M
    Svobodnik, A
    Kaplanova, J
    Kadlec, B
    Palkova, I
    Babickova, L
    Stratil, D
    Nebesky, T
    LUNG CANCER, 2005, 49 : S376 - S376
  • [3] Gefitinib ('Iressa'): a new therapy for advanced non-small-cell lung cancer
    Reck, M
    Gatzemeier, U
    RESPIRATORY MEDICINE, 2005, 99 (03) : 298 - 307
  • [4] The lifetime cost of gefitinib ("Iressa") in treating patients with non-small-cell lung cancer (NSCLC)
    Haiderali, A
    Chin, W
    VALUE IN HEALTH, 2004, 7 (06) : 671 - 671
  • [5] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    LUNG CANCER, 2003, 41 : S23 - S28
  • [6] New perspectives in the management of non-small cell lung cancer (NSCLC): Gefitinib (Iressa, ZD 1839)
    Manegold, C
    EJC SUPPLEMENTS, 2004, 2 (04): : 34 - 39
  • [7] PREDICTIVE FACTORS ASSOCIATED WITH GEFITINIB RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Xu, F.
    Zhou, T.
    Duan, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [8] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
    Chen, Lian
    Chen, Rui
    Zhu, Zhe
    Zhang, Yichen
    Wen, Zhengwei
    Li, Yun
    Li, Xiaoming
    Luo, Yuwen
    Ma, Liyu
    Lin, Shuguang
    Chen, Xin
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (04) : 466 - 470
  • [9] PRELIMINARY RESULTS OF ANTITUMOR ACTIVITY OF GEFITINIB (IRESSA™) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ON A COMPASSIONATE USE PROTOCOL
    Di Emidio, K.
    Barbieri, F.
    Bavieri, M.
    Pifferi, M.
    Marchioni, A.
    Fabbri, L. M.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2004, 15 : 32 - 32
  • [10] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer(NSCLC)
    Lian Chen
    Rui Chen
    Zhe Zhu
    Yichen Zhang
    Zhengwei Wen
    Yun Li
    Xiaoming Li
    Yuwen Luo
    Liyu Ma
    Shuguang Lin
    Xin Chen
    Chinese Journal of Cancer Research, 2014, 26 (04) : 466 - 470
12345